NCT05848505View on ClinicalTrials.gov

Opioid-sparing Effect of Intranasal Dexmedetomidine

NACompletedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

February 25, 2022

Primary Completion Date

December 20, 2022

Study Completion Date

December 20, 2022

Conditions

Tonsillar Hypertrophy

Interventions

DRUG

Dexmedetomidine

Intranasal administration Dosage 2 mcg/kg

Trial Locations (1)

51900

Sheikh Khalifa Medical City, Abu Dhabi

All Listed Sponsors

lead

Pierre-Yves P Lequeux

OTHER